Major Depressive Disorder

The experts weighed in on a wide variety of psychiatric issues for the February 2024 issue of Psychiatric Times.

Diagnosing this intricate comorbidity demands a nuanced approach. Here's what you need to know.

Clinical trial compares outcomes with behavioral activation psychotherapy or antidepressant medication for depression in patients with heart failure.

Check out this broad range of innovative medications in development with the goal of providing psychiatric clinicians with novel treatments in the quest to decrease patient suffering and improve function and quality of life.

From pain and suicidality in patients with depression to digital mental health interventions for adolescents with eating disorders, here are highlights from the week in Psychiatric Times.

“I wish I were dead.” Researchers performed a meta-analysis of psychological pain and suicidality in patients with depression.

From the impact of BMI on clinical features of bipolar disorder to FDA approval of the first integrated TMS system for MDD and OCD, here are highlights from the week in Psychiatric Times.

What is new in research on depression?

The FDA granted clearance for a transcranial magnetic stimulation technology indicated for major depressive disorder and obsessive-compulsive disorder.

From a groundbreaking new launch for PTSD in the United States to connections between antidepressant treatment and metabolic syndrome, here are highlights from the week in Psychiatric Times.

Will this medication make me gain weight? Researchers analyzed response to antidepressant treatment as a predictor of incident metabolic syndrome in a cohort of patients with depression.

Review the uses and forms of transcranial magnetic stimulation.

Could fish oil replace antidepressants as a first-line pill for depression?

Psychiatric treatment works to a degree comparable to other branches of medicine which address complex, chronic illnesses.

From a new look at the famous STAR*D study to updates from the National Academy of Sciences Conference on Adult ADHD, here are highlights from the week in Psychiatric Times.

Since 2006, STAR*D stands out as an icon guiding treatment decisions of major depressive disorder. But what if it is broken?

From adjunctive cariprazine for the treatment of major depressive disorder to a new app for prescribing antidepressants and antipsychotics, here are highlights from the week in Psychiatric Times.

ECT: a gold-standard treatment for major depressive disorder. Ketamine/esketamine: a newer therapeutic option. This ACNP 2023 Annual Meeting session took a deeper look.

This ACNP 2023 Annual Meeting poster covered a 26-week study on cariprazine as an adjunctive treatment to antidepressants in patients with major depressive disorder.

Neurosteroid therapeutics could be the solution to provide fast-acting treatment for mothers with postpartum depression.

DBS in psychiatry: What challenges stand between this treatment and success? Alik Widge, MD, PhD, shares more at the ACNP 2023 Annual meeting.

Did you catch the President's Plenary at the ACNP 2023 Annual Meeting?

Navacaprant—a novel, oral, once-daily, highly selective kappa opioid receptor antagonist that is currently in phase 3 development as a monotherapy for major depressive disorder.

Clinicians discuss past treatment options compared to novel glutamate-modulating agents, highlighting their rapid onset of symptom relief.